How biopharma companies are bolstering R&D pipeline through deal-making
How biopharma companies are bolstering R&D pipelines through deal-making
Sourcing research externally seems to be the preferred path for biopharma companies to strengthen their R&D pipeline. But when choosing from the three main options open to them—licensing, mergers and acquisitions, and joint ventures—what factors should they examine, and do deal types differ in the ways they accelerate development and deliver long-term value?
For biopharma, value-based competition is likely the new reality regardless of policy
By Ralph Marcello, Principal, Deloitte Consulting LLP
Many biopharma companies are under growing pressure from policy makers on both sides of the aisle – as well as from state and federal regulators and lawmakers.
Value-based care and medical technology
Assessing the value of medtech products and offerings
The health care ecosystem is in the midst of a shift from volume-based, fee-for-service (FFS) systems to value-based care (VBC) models. AdvaMed launched a Strategic Value Initiative with Deloitte Consulting LLP to develop principles and an approach for assessing the value of medical technologies.